No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Asymchem Laboratories (Tianjin) Co., Ltd. functions as a contract development and manufacturing organization (CDMO), offering its expertise to pharmaceutical and biotechnology companies both globally and within Mainland China. Their services encompass drug research, development, and production, supporting projects across the entire drug lifecycle, from early clinical phases to commercial scale. This includes R&D and cGMP-compliant manufacturing of advanced intermediates, active pharmaceutical ingredients (APIs), and finished drug formulations, in addition to providing clinical research support. Furthermore, Asymchem engages in pharmaceutical analysis and testing, the distribution (wholesale, retail, and direct sale) of medicines, and initiatives focused on advancing pharmaceutical science and technology. The company, established in 1999, maintains its headquarters in Tianjin, China.
www.asymchem.com.cnNo one on the platform currently holds 002821.SZ.
No tracked institution reports a position in 002821.SZ as of their last filing.
No one on the platform has traded 002821.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 9.5% | 16.0% | 20.0% | — | — | — |
| Rev. Growth % | 14.9% | 16.3% | ||||
| Profit Margin % | 17.0% | 23.5% | 23.3% | |||
| Free Cash Flow Margin % | 2.1% | 2.3% | -1.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $8.1B | +21.8% | $3.75 | $3.66–$3.84 | — | 3 |
| 2027 | $9.8B | +21.2% | $4.99 | $4.43–$5.59 | — | 4 |
| 2028 | $11.8B | +20.6% | $6.36 | $6.01–$7.08 | — | 2 |
| 2029 | $20.0B | +68.8% | $15.38 | $14.54–$17.13 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 1 of the last 2 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2025-03-28 | $0.24 | $0.68 | +183.3% |
| 2024-10-29 | $1.20 | $0.61 | -49.2% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 002821.SZAsymchem Laboratories (Tianjin) Co., Ltd. | $180.45 | +1.83% | $60.1B | — |
| 000513.SZLivzon Pharmaceutical Group Inc. | $26.29 | -1.09% | $23.3B | — |
| 002007.SZHualan Biological Engineering Inc. | $12.75 | -0.86% | $23.3B | — |
| 002603.SZShijiazhuang Yiling Pharmaceutical Co., Ltd. | $15.16 | -0.26% | $25.3B | — |
| 002773.SZChengdu Kanghong Pharmaceutical Group Co., Ltd |
| $19.12 |
| -0.05% |
| $17.6B |
| — |
| 300759.SZPharmaron Beijing Co., Ltd. | $42.90 | +1.27% | $63.4B | — |
| 600079.SSHumanwell Healthcare (Group) Co.,Ltd. | $18.38 | -0.65% | $30.0B | — |
Source: Financial Modeling Prep · peers by sector/industry